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Background: Exercise training improves exercise tolerance in chronic obstructive pulmonary 
disease (COPD). Tiotropium 18 μg once daily induces sustained bronchodilation throughout the 
day and reduces hyperinﬂ  ation, one of the pathophysiological factors contributing to exertional 
dyspnea in COPD patients.
Aim: To determine whether tiotropium enhances the effects of exercise training in patients 
with COPD.
Design: Multicenter, 25 week randomized, double-blind, placebo-controlled, parallel-group 
study.
Setting: Twelve Italian Pulmonary Units practicing pulmonary rehabilitation.
Patients and intervention: Two hundred thirty four COPD patients (196 males; mean 
age: 67.4 ± 7.6; forced expiratory volume at 1 second (FEV1): 41.4 ± 13.0% predicted) were 
randomised to tiotropium 18 μg or placebo inhalation capsules taken once daily. Both groups 
underwent a 8 week pulmonary rehabilitation program (PR) consisting of 3 exercise training 
session per week.
Measurements: Baseline, at the end of PR and after 12 weeks, patients completed pulmonary 
function testing, six minute walking test (6MWT), the Baseline and Transition Dyspnea Index 
(BDI and TDI), and the St. George’s Respiratory Questionnaire (SGRQ).
Results: Relative to placebo, tiotropium had larger trough and post-study drug FEV1 responses 
on all test days. At the end of and 12 weeks following PR, patients on tiotropium showed no 
statistically signiﬁ  cant differences in 6MWT compared to patients on placebo. Compared to 
the period immediately prior to PR, the mean improvement in 6MWT was only 29.7 meters 
(7.1%) for the combined cohort. Mean TDI focal scores at the end of PR were 3.60 for tiotro-
pium and 2.25 for placebo (p   0.01). At 12 weeks after PR, TDI focal scores were 2.71 for 
tiotropium and 2.11 for placebo (p = 0.16). Reduction in all four SGRQ component scores, 
indicating an improvement in health-related quality of life, was observed for the tiotropium 
group over the duration of the study compared to placebo but the differences were not statisti-
cally signiﬁ  cant. During the study period, there were fewer exacerbations and exacerbation 
days in the tiotropium group.
Conclusion: Although signiﬁ  cant improvements were observed with perceived dyspnea, 
compared to placebo, the addition of tiotropium to pulmonary rehabilitation did not improve 
the 6MWT.
Keywords: bronchodilators, pulmonary rehabilitation, health-related quality of life, 
hyperinﬂ  ation, dyspnea
Introduction
Chronic obstructive pulmonary disease (COPD) affects 6% of the general population and 
is a leading cause of morbidity and mortality and health-care costs worldwide (Mannino 
and Buist 2007). It is a heterogeneous disorder due to dysfunction of the small and large 
airways, as well as by destruction of the lung parenchyma and vasculature, in highly International Journal of COPD 2008:3(4) 772
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variable combinations (Celli et al 2004). Breathlessness 
and reduction in exercise capacity are the main complaints 
of COPD patients. These symptoms progress relentlessly 
reducing the patients’ ability to perform activities of daily 
living (Pitta et al 2005). Different pathophysiological factors 
may contribute to exertional dyspnea in COPD patients: 
increased intrinsic mechanical loading on inspiratory muscles 
due to the intrinsic positive end-expiratory pressure, airﬂ  ow 
limitation, inspiratory muscle weakness, increased ventilatory 
demand relative to capacity, gas exchange abnormalities, 
cardiovascular factors (Ambrosino and Serradori 2006). In 
COPD, exercise dyspnea correlates with lung hyperinﬂ  ation, 
as assessed by inspiratory capacity, which, in turn, results in 
neuromechanical dissociation. Peripheral muscle dysfunction 
is also an important determinant of exercise capacity in 
COPD (Saey and Maltais 2005).
Moderate to very severe COPD patients may obtain 
improvement in dyspnea, exercise capacity, and health-
related quality of life (HRQL) as a result of exercise training, 
a component of pulmonary rehabilitation (PR) (Nici et al 
2006). The improvements in exercise tolerance induced 
by training have been found to be based on physiological 
changes, such as cardio-respiratory and peripheral muscle 
adaptations (Casaburi et al 1991; Maltais et al 1996) and 
are independent of the pattern of exercise-induced dynamic 
hyperinﬂ  ation (Georgiadou et al 2007).
Tiotropium, an inhaled anticholinergic drug, provides 
sustained 24-hour improvement in airﬂ  ow limitation and 
reduces hyperinﬂ  ation with once-daily dosing (O’Donnell 
et al 2004). Data have also shown that tiotropium improves 
exercise tolerance, and HRQL (Aaron et al 2007). In addition, 
tiotropium in combination with PR improves exercise 
endurance time on treadmill, dyspnea and health status 
compared to PR alone; an effect sustained for 3 months 
following PR completion (Casaburi et al 2005).
The primary objective of the present study was to 
determine whether tiotropium, compared to placebo, 
enhances the improvement in exercise tolerance as measured 
by the six minute walk test (6MWT) in patients with COPD 
who participate in PR. The secondary objectives included 
an assessment of the impact of tiotropium on dyspnea and 
HRQL following PR. In addition, the study sought to evaluate 
whether the beneﬁ  ts after the conclusion of PR are better 
maintained with tiotropium.
Materials and methods
The study was approved by all local Independent Ethics 
Committees and was performed according to the Helsinki 
Declaration; written informed consent was obtained from 
each patients prior to participation.
Study design
This was a 25-week, multicenter, randomized, double-blind, 
placebo-controlled, parallel group study to evaluate the 
efﬁ  cacy of tiotropium in patients with COPD participating in 
PR, conducted in 12 sites in Italy. Patients were randomized 
1:1 to either tiotropium 18 μg qd or placebo for 25 weeks. 
Tiotropium or matching placebo were supplied as a 
dry-powder capsule delivered by the HandiHaler® device 
(Boehringer Ingelheim; Ingelheim, Germany) and inhaled in 
the morning. The concomitant regular use of oral ( 10 mg/d 
of prednisone or equivalent) and inhaled steroids, short 
acting theophylline preparations, and mucolytic agents not 
containing bronchodilators was allowed during the study if 
the medication had been started for at least 6 weeks prior 
to the screening visit. Open-label salbutamol metered-dose 
inhaler was supplied during the study for as-needed acute 
symptom relief. Other β2-agonists (long- and short-acting) 
and inhaled anticholinergic medications (other than study 
drugs) were not permitted.
Patients
Patients were required to have a clinical diagnosis of COPD 
(ATS 1995a), forced expiratory volume in one second 
(FEV1)  60% of predicted, and FEV1   70% of forced vital 
capacity (FVC). They were required to be at least 40 years of 
age and to have a smoking history ( 10 pack-years). Patients 
with a history of asthma, allergic rhinitis, eosinophils  8% 
were excluded from the study as well as patients with recent 
respiratory tract infections. Also, patients with signiﬁ  cant 
diseases other than COPD or a recent history of myocardial 
infarction, hospitalisation for heart failure and cardiac 
arrhythmia requiring drug therapy, were not eligible for the trial. 
Other exclusion criteria included orthopedic, muscular, or neu-
rologic disease that would interfere with regular participation 
in aerobic exercise or with exercise testing as well as a body 
mass index (BMI)  30 or  18 kg m2. Patients who were in a 
PR program at the time of screening were also excluded.
Study protocol
The study protocol is described in Figure 1. During an initial 
screening visit (Visit 1), patients performed pulmonary 
function tests (PFTs) and performed the 6-minute walking 
test (6MWT). One week following the initial screening, 
patients were randomised to tiotropium or placebo for the 
subsequent 25 weeks. Following randomization, patients International Journal of COPD 2008:3(4) 773
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entered a 4-week period during which they received study 
drug but not PR. PFTs and the 6MWT were repeated at the 
beginning (Visit 2) and end of this 4 week period (Visit 3). 
Patients then entered an 8-week PR program (Visit 4). After 
the last PR session (Visit 6), patients continued on study 
medication for a 12 week follow-up period. 6MWT were 
performed at the conclusion of the 8 weeks of PR (Visit 6) 
and after the 12 weeks of follow-up (Visit 9).
Measurements
Lung function
Spirometry was conducted according to the American 
Thoracic Society (ATS) criteria (ATS 1995b). The predicted 
values were calculated according to Quanjer (1983). The 
tests were performed at the screening visit; at randomisation 
(Visit 2); after 4 weeks of treatment (Visit 3); after PR 
(Visit 6) and after the 12-week follow-up period (Visit 9). 
Tests were performed prior to and 1 hour after dosing.
Exercise
Exercise tolerance was evaluated at the screening visit; 
at randomisation (Visit 2), which served as the baseline 
measurement; after 4 weeks of treatment (Visit 3); after PR 
(Visit 6) and after the 12-week follow-up period (Visit 9) by 
the 6MWT according to standard guidelines (ATS 2002). 
The best result of three tests was recorded. Except for Visits 1 
and 2, all 6MWTs commenced 90 minutes after inhalation 
of study drug and approximately 15 to 30 minutes after 
spirometry. Arterial oxygen saturation was monitored by 
pulse oximetry throughout testing.
Dyspnea
Italian versions of the Baseline Dyspnea Index (Visit 2) and 
the Transition Dyspnea Index (TDI) (Mahler et al 1984) were 
used to assess dyspnea (Visits 3, 6 and 9). During the 6MWT, 
patients were asked to rate the intensity of dyspnea using the 
modiﬁ  ed Borg scale every two minutes (Borg 1992).
Health-related quality of life
HRQL was evaluated by a validated Italian translation of the 
St. George’s Respiratory Questionnaire (SGRQ) at Visits 2, 
3, 6, and 9 (Carone et al 1999).
Exacerbations and hospitalizations
For the purpose of this study, exacerbations were deﬁ  ned as 
episodes (new onset or worsening of at least 2 respiratory 
symptoms) witha duration of 3 days or more requiring 
systemic steroids or antibiotics.
Pulmonary rehabilitation program
The lower limb exercise training protocols were performed on 
a treadmill 3 times weekly for 8 weeks. Initial treadmill speed 
was set to attain a targeted heart rate at 80% of the maximum 
heart rate obtained during the 6MWT at Visit 3. Dyspnea 
by the modiﬁ  ed Borg scale, heart rate, pulse oximetry and 
treadmill speed was recorded every 10 minutes. Training was 
maintained for as long as tolerated for at least 30 minutes. For 
patients unable to complete 30 minutes of continuous lower 
limb exercise, exercise training sessions could be divided into 
as many as 4 parts with 5 to 10 minute rests in between.
Other exercise modalities were encouraged. All patients 
were encouraged to exercise at home on days when they were 
not attending the centre. Pulmonary rehabilitation included 
also upper limb activities as well as patient education. 
The form of these activities were determined by each centre 
and was not speciﬁ  ed within the protocol.
Statistical analysis
For the primary analysis, a full analysis set (FAS) that 
included all patients randomized and treated with a baseline 
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Figure 1 Outline of study protocol.
Abbreviations: BDI, baseline dyspnea index; PFT, pulmonary function test; SGRQ, St. George’s Respiratory Questionnaire; 6MWT, 6 minute walk test.International Journal of COPD 2008:3(4) 774
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6MWT value and at least one 6MWT value on treatment 
available, was considered. In order to be able to include the 
same patients at each time point in the 6MWT summaries, 
missing post baseline values caused by a patient’s intake 
of rescue medication or a patient’s early discontinuation 
due to worsening of COPD disease were replaced by the 
minimum value at the previous visits. For missing values 
due to other reason were replaced by the median of all 
nonmissing distance on that visit. The two treatments groups 
were compared using an analysis of covariance (ANCOVA) 
model that included terms for center and treatment as main 
effects and baseline (data at Visit 2) as a linear covariate. 
Interactions: centers-by-treatment and treatment-by-baseline 
were also tested adding appropriate terms to the main 
ANCOVA model.
Treatment differences are presented as least square 
means ± standard error (SE) and corresponding p-values taken 
from ANCOVA. Because of the a pre-speciﬁ  ed null hypothesis 
testing procedure (at a 2-sided α level of 0.05) on a single 
primary variable, no adjustment for multiplicity was required. 
A sensitivity analysis was performed on the primary variable 
considering the per protocol set (PPS) that included patients 
in FAS and without important protocol violations.
The spirometry measurements (FEV1 and FVC), TDI 
scores and SGRQ scores were analysed on the FAS using 
the same main model speciﬁ  ed for the primary endpoint with 
imputation for missing data.
Continuous baseline characteristics are shown as 
mean ± standard deviation (SD) and were compared between 
the two treatment groups by using the Mann-Whitney-Wilcoxon 
test or when appropriate the t-test. Categorical baseline 
characteristics are expressed as counts and percentages and were 
compared between groups by using the chi-squared test.
Sample size
A sample of 182 patients (91 per treatment group) was calcu-
lated as adequate to detect a 54 meter (Redelmeier et al 1997). 
difference between tiotropium and placebo at 5% signiﬁ  cance 
level, with 80% power using a two-tailed t-test. Assuming 
a 20% attrition rate, the total planned sample size was 220. 
All the statistical analyses were performed using the SAS 
package (version. 8.2, SAS Inc., Cary, NC, USA).
Results
Patients recruited, eligible withdrawals and completions are 
shown in Figure 2. Overall, 177 patients (87 tiotropium, 
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90 placebo) completed the trial according to the protocol. 
Of the 57 patients prematurely discontinued, 30 (25.6%) had 
been randomized to tiotropium and 27 (23.1%) to placebo. 
The reasons for discontinuation are also shown in Figure 2 
was consent withdrawn (9.4% of treated patients). The FAS 
included 103 patients in the tiotropium group and 106 patients 
in the placebo group. There were 154 (75 on tiotropium, 79 
on placebo) patients in the PPS.
At study entry, the patients’ baseline characteristics 
were balanced between the two groups (Table 1). The 
percentage of patients taking any pulmonary medication at 
baseline period was nonsigniﬁ  cantly higher in the placebo 
than in the tiotropium group (60.7% vs 53.0%, p = 0.24). 
At baseline 23.9% of patients in the placebo and 14.5% 
in the tiotropium group were receiving inhaled anticholin-
ergics. The percentage of patients taking any pulmonary 
medication during the treatment period (other than that 
supplied as part of the trial) was 54.7% for both groups. 
The use of inhaled steroids during the treatment period 
was 41.9% for the tiotropium vs 52.1% for the placebo 
group (p = 0.12). The proportion of patients performing 
either arm exercise or exercising at home was similar for 
both groups.
Lung function
Tiotropium signiﬁ  cantly increased post-dose FEV1 at week 
13 and 25 compared to placebo (adjusted mean differences 
(AMD) between groups 0.103 ± 0.052 L, 0.122 ± 0.052 L 
and 0.110 ± 0.049 L on test week 4, 13 and 25, respectively; 
p   0.05 on all test days).
Patients receiving tiotropium had larger trough FEV1 
responses than patients receiving the placebo on all the test 
days (AMD between groups: 0.100 ± 0.05 L on test week 4; 
p = 0.047). The trough AMD on the other two test days were 
not statistically signiﬁ  cant.
Tiotropium signiﬁ  cantly increased post-dose FVC on all 
test days compared to placebo (AMD between groups: 0.154 ± 
0.064 L, 0.176 ± 0.067 L and 0.121 ± 0.061 L on the test 
days 29, 92 and 176, respectively; p   0.05 on all test days) 
Tiotropium increased trough FVC compared to placebo (AMD 
between groups: 0.124 ± 0.061 L, 0.125 ± 0.065 L and 0.102 ± 
0.063 L on test week 4, 13, and 25, respectively, the difference 
on test week 4 being statistically signiﬁ  cant: p = 0.044).
Exercise tolerance
The adjusted means of 6MWT on each test day are presented 
in Figure 3. At Visit 3, after 29 days of treatment, patients 
Table 1 Baseline characteristics of patients in study*
Total treated [N] Placebo Tiotropium All p-value
117 117 234
Male [N (%)] 99 (84.6) 97 (82.9) 196 (83.7) 0.72°
Age (yrs) 66.9 ± 7.3 67.8 ± 7.8 67.4 ± 7.6 0.38§
Duration of COPD (yrs) 11.3 ± 9.5 10.9 ± 9.8 11.1 ± 9.6 0.66#
BMI (kg/m2) 26.7 ± 4.0 26.4 ± 4.0 26.6 ± 4.0 0.57§
Smoking history – pack/years 35.0 ± 22.4 38.3 ± 25.2 36.7 ± 23.8 0.33#
FEV1 (L) 1.1 ± 0.4 1.1 ± 0.4 1.1 ± 0.4 0.62§
FEV1 (% predicted) 40.3 ± 12.6 42.5 ± 13.3 41.4 ± 13.0 0.20§
FEV1/FVC (%) 45.2 ± 10.4 47.3 ± 11.8 46.3 ± 11.2 0.15§
FVC (L) 2.5 ± 0.8 2.4 ± 0.7 2.5 ± 0.8 0.54§
6MWT (meters) 402 ± 119.5 404.8 ± 115.6 403.4 ± 117.3 0.86§
Baseline pulmonary medication†:
Total taking pulmonary medication [N (%)] 71 (60.7) 62 (53.0) 133 (56.8) 0.23°
Anticholinergics (Short-acting/inhaled) 28 (23.9) 17 (14.5) 45 (19.2) 0.07°
Beta-adrenergics (Long-acting/inhaled) 28 (23.9) 13 (11.1) 41 (17.5) 0.01°
Beta-adrenergics (Oral/short-acting/inhaled) 39 (33.3) 32 (27.4) 71 (30.3) 0.32°
Steroids (Oral/inhaled/IV/IM) 60 (51.3) 44 (37.6) 104 (44.4) 0.04°
Xanthines 28 (23.9) 28 (23.9) 56 (23.9) 1.0°
Notes: *Data are presented as mean ± standard deviation unless otherwise indicated; °p-value based on chi-squared test; §p-value based on t-test; #p-value based on 
Mann-Whitney-Wilcoxon test; †Only frequent ( 10%) pulmonary medication were reported.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity.International Journal of COPD 2008:3(4) 776
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on tiotropium walked nonsigniﬁ  cantly longer than those on 
placebo (423.8 ± 5.9 vs 411).1 ± 5.7 meters respectively: 
AMD between groups: 12.7 ± 8.0 meters, 95% conﬁ  dence 
interval [CI] −3.1 to 28.5, p = 0.12). After 13 weeks of 
treatment, including 8 weeks of PR (Visit 6, day 92), 
patients on tiotropium showed a nonsigniﬁ  cant longer walk 
distance compared to those on the placebo (450.8 ± 7.0 vs 
443.5 ± 6.8 meters, respectively, AMD: 7.3 ± 9.5 meters, 
95% CI −11.4 to 26.1, p = 0.44). Compared to the period 
immediately prior to PR, the mean improvement in 6MWT 
was only 29.7 meters (7.1%) for the combined cohort. After 
25 weeks of treatment, 12 weeks after the termination of 
the PR (Visit 9, day 176), patients in both groups showed 
a reduction in exercise capacity without any signiﬁ  cant 
difference between groups (AMD −6.8 ± 9.3 meters, 95% 
CI −25.1 to 11.5, p = 0.46).
The primary analysis was also performed on the PPS 
data set. Patients on tiotropium walked longer distance 
on all the test days. The AMD between the two groups on 
Visit 3 (day 29) was 21.0 ± 8.6 meters, 95% CI 4.0 to 37.9, 
p = 0.02. The AMD on the other two test days (92 and 176) 
were 13.2 ± 11.3 and 5.1 ± 10.9, (p = 0.24 and p = 0.64, 
respectively).
Dyspnea
The mean BDI score was 6.6 units for both treatment groups. 
As shown in Figure 4 from test day 29 to 92 (at the end of 
PR), both treatment groups showed increases in the mean 
TDI focal scores, with the tiotropium group showing a 
larger increase (2.25 ± 0.29 vs 3.60 ± 0.30, p = 0.001) and 
exceeded the minimal clinically important difference (MCID) 
of 1 unit. The differences on the test days 29 and 176 were 
not statistically signiﬁ  cant. Of note, both the placebo and 
tiotropium treatment groups improved by more than 1 unit 
at day 29 (1.21 ± 0.22 vs 1.45 ± 0.23, p = 0.44).
Health-related quality of life
The SGRQ total score improved after treatment and then 
remained stable in both groups, and trended towards a lower 
score on each test day in tiotropium compared to placebo 
group, which did not reach statistical signiﬁ  cance (Figure 5). 
The mean change from baseline was −2.1 units (37.0 vs 39.1) 
in the placebo group and −3.5 units (35.6 vs 39.1) in the 
tiotropium group at day 29. The changes from baseline to 
day 92 were −6.1 units (33.1 vs 39.1) in the placebo group 
and −8.1 units (30.9 vs 39.1) in the tiotropium group. The 
changes on day 176 were −6.0 units (33.1 vs 39.1) and 
−7.3 units (31.8 vs 39.1) in the placebo and tiotropium 
groups, respectively. Improvements in both groups exceeded 
the MCID of 4 units at the end of PR and the end of the 
follow-up period.
Exacerbations and hospitalizations
The proportion of patients suffering from at least one COPD 
exacerbation was 13.6% (14/103 patients) in the tiotropium 
and 19.8% (21/106 patients) in the placebo group, with a 
relative risk reduction of 31.3% (p = 0.23). The total number 
of COPD exacerbations were 19 in the tiotropium and 26 in 
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the placebo group. The total COPD exacerbation days were 
318 in the tiotropium and 361 in the placebo group (p = 0.21). 
There were 2 COPD exacerbations leading to hospitalizations 
in tiotropium and 6 in the placebo group.
Discussion
In the present clinical trial, compared to placebo, tiotropium 
in combination with pulmonary rehabilitation signiﬁ  cantly 
improved dyspnea (day 92) but did not show any additional 
benefit to PR in exercise tolerance, as measured by 
the 6MWT. Relatively minor changes were observed in 
the 6MWT in both groups with PR. There were clinically 
meaningful improvements in dyspnea (ie, TDI focal 
score  1 unit) in both groups prior to, which improved 
further after PR. Improvement in HRQL was larger in 
tiotropium than in placebo group although differences 
were not statistically signiﬁ  cant. In both groups, large 
changes in the SGRQ total score were observed after PR 
which were relatively well maintained during the 12 week 
follow-up period.
Evidence-based support for PR in the management of 
COPD patients has accumulated in the last decade, and 
this comprehensive intervention has been unequivocally 
demonstrated to reduce dyspnea, increase exercise 
performance, and improve HRQL. Furthermore, an emerging 
literature is beginning to reveal its effectiveness in reducing 
health care costs (Nici et al 2006). The hypothesis of this 
study was that in terms of aerobic conditioning, there 
might be an advantage of tiotropium administered during 
a period of exercise training. Tiotropium induces sustained 
bronchodilation throughout the day and has superior 
spirometric outcomes in comparison to placebo or ipratro-
pium bromide. In addition, several studies demonstrated 
sustained reductions in hyperinflation with tiotropium 
(O’Donnell et al 2004; Maltais et al 2005). These outcomes 
might be enough to allow patients to exercise longer or 
with a higher intensity thereby leading to improved exercise 
tolerance (Maltais et al 2005). Furthermore, the beneﬁ  ts 
gained may have a longer lasting effect due to the higher 
exercise tolerance attained. However, the relatively modest 
improvement in exercise tolerance following PR in both 
groups in the present study appears to be contrary to those 
of Casaburi et all (Casaburi et al 2005).
The explanation for the modest improvement in exercise 
capacity to either PR or to tiotropium in the present study 
likely relates to methodologic issues including the choice of 
functional measurement of endurance. A similar rationale 
also can explain the differing results between the present 
trial and the Casaburi study (Casaburi et al 2005). In the 
report by Casaburi, the effect of tiotropium on exercise 
tolerance in patients with COPD participating in 8 weeks 
of PR was measured by endurance time during a constant 
work rate treadmill exercise test, whereas in our study we 
used the 6MWT. Although strong relationships between 
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different methods of exercise assessment have been reported 
(Turner et al 2004), the two methods evaluate aspects 
somehow different of exercise, which may explain the 
differences in results between the two studies. The relative 
responsiveness of the 6MWT to detect changes in exercise 
performance following bronchodilation and PR appears to 
be lower than other forms of exercise testing. Pepin and 
colleagues (2007) explored the sensitivity of the 6MWT 
to acute bronchodilation compared with the endurance 
shuttle walk test. Despite demonstrating acute spirometric 
improvements, the 6MWT distance did not improve; 
however, improvements were evident in the shuttle 
walk test.
The results probably were likely inﬂ  uenced by patient 
selection. At baseline, the patients had a relatively well 
preserved 6MWT (mean   400 metres), which could 
have potentially led to ceiling effect. Another explanation 
includes variability in the conduct of the test due to the 
enrolment of multiple sites with variable experience. For 
example, despite training in the conduct of the study, several 
centres did not adhere performance of protocol mandated. 
As well, many centres tended to round the 6MWT results 
to the closest 10 meter value rather than determine the 
single digit result. There was also variability in the physical 
construction of the test (ie, variability in the length of 
the corridor).
Twelve weeks after the termination of PR, patients in 
both groups showed a reduction in exercise capacity without 
any signiﬁ  cant difference between groups. Limited studies 
suggest that the beneﬁ  ts of PR decline toward baseline after 
6 to 12 months, but remain improved compared with control 
subjects after 1 year (Foglio et al 1999).
The modest changes observed in the 6MWT appeared 
to be contrary to the clinically meaningful changes in the 
TDI focal score. The tiotropium group reported the lowest 
perception of dyspnea. It might therefore be assumed that 
tiotropium treated patients could engage in a longer duration 
and/or more intense physical activity compared to the placebo 
group. In a subgroup analysis of the study initially reported 
by Casaburi and colleagues (2005), tiotropium appeared 
to increased patient self-reported participation in physical 
activities (Kesten et al 2008). In the present study from test 
week 4 to 13 both treatment groups showed increases in the 
TDI scores, indicating an improvement in dyspnea, with the 
tiotropium group showing a signiﬁ  cantly larger increase on test 
week 13 (after the PR period), but not on test week 4 and test 
week 25. The difference in the TDI focal score from placebo 
at the conclusion of PR (day 92) exceeded the MCID of 1 unit. 
It has been suggested that the categorisation of patients with 
COPD according to the level of dyspnea is more discriminating 
than staging of disease severity on the basis of airway obstruc-
tion with respect to 5-year survival (Nishimura et al 2002).
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The observed apparent dissociation of 6MWT and 
dyspnea was also observed for the SGRQ. In both groups, 
PR resulted in rather dramatic improvements in SGRQ total 
score that exceeded the MCID of 4 units. The SGRQ total 
score was lower on each test day in the tiotropium compared 
to the placebo group although the differences were not 
statistically signiﬁ  cant. As opposed to the 6MWT, the SGRQ 
remained stable following PR (Figure 4). This observation 
has been reported also in other studies (Foglio et al 1999, 
2007) and probably reﬂ  ects the comprehensive nature of the 
PR and the fact that health status depends on more than just 
exercise capacity. Studies in COPD patients using both the 
Chronic Respiratory Questionnaire and SGRQ (Ketelaars 
et al 1996; Tsukino et al 1996) have shown that HRQL is only 
partially determined by lung function and exercise tolerance. 
Therefore, HRQL should be speciﬁ  cally evaluated in addition 
to physiological measures before and after PR. Furthermore 
it has been reported that generic and disease speciﬁ  c HRQL 
are independent risk factors for respiratory and all-causes 
mortality (Domingo-Salvany et al 2002).
The present study documented improvements in 
spirometry and a trend towards reduced exacerbations. 
While spirometry is not expected to improve with PR, it was 
expected that tiotropium would show similar improvements 
to other published reports (O’Donnell et al 2004; Maltais et al 
2005). Patients receiving tiotropium had larger trough FEV1 
and FVC responses than those receiving placebo on all the test 
days, although the mean difference between the tiotropium 
and the placebo group was signiﬁ  cant only on test day 29. 
Tiotropium signiﬁ  cantly increased patients post-dose FEV1 
and FVC on all the test days compared to placebo. These 
improvements were higher than those observed in the study 
by Casaburi and colleagues (2005) in which more severe 
patients were enrolled. The lack of statistically signiﬁ  cant 
differences in trough values at test days 92 and 176 between 
the two treatments groups was unexpected and could be 
explained by a larger variability observed in spirometry 
outcomes in the present study.
In summary, tiotropium in combination with PR 
signiﬁ  cantly improved dyspnea at the end of the program but 
did not show any additional beneﬁ  t in the 6MWT, compared 
to PR and placebo. We encountered methodological issues 
regarding the 6MWT in the present study. The relatively 
modest changes in the 6MWT with PR in the trial suggest that 
the use of this ﬁ  eld test in multicenter clinical trials may have 
limitations not fully understood or reported. Alternative tests 
of functional capacity should be considered in multicenter 
COPD clinical trials.
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